<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="100008"><DrugName>macrocyclic ligands (idiopathic pulmonary fibrosis), Fidelta</DrugName><DrugSynonyms><Name><Value>macrocyclic ligands (idiopathic pulmonary fibrosis), Fidelta</Value></Name></DrugSynonyms><CompanyOriginator id="1009875">Fidelta Ltd</CompanyOriginator><CompaniesSecondary><Company id="1009875">Fidelta Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1009875" type="Company"><TargetEntity id="5035536114" type="organizationId">Fidelta doo</TargetEntity></SourceEntity><SourceEntity id="3771" type="ciIndication"><TargetEntity id="J84.112" type="ICD10"/><TargetEntity id="10021240" type="MEDDRA"/><TargetEntity id="D054990" type="MeSH"/><TargetEntity id="2032" type="ORPHANET"/><TargetEntity id="-1110748304" type="omicsDisease"/><TargetEntity id="289" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="3771">Idiopathic pulmonary fibrosis</Indication></IndicationsSecondary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-04-02T03:28:10.000Z</LastModificationDate><ChangeDateLast>2018-04-02T00:00:00.000Z</ChangeDateLast><AddedDate>2015-11-26T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1009875" linkType="Company"&gt;Fidelta&lt;/ulink&gt; was investigating a program of macrocyclic ligands  for the potential treatment of idiopathic pulmonary fibrosis (IPF).  In November 2015, lead identification was ongoing [&lt;ulink linkID="1715562" linkType="Reference"&gt;1715562&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2015, preclinical data were presented at the First RSC-SCI Fibrosis Disease Symposium, Slough, UK. One compound produced 66% inhibition of LPS challenge at 23 mg/kg and was active    at doses as low as 1 mg/kg. It had low oral bioavailability but was as effective as 100 mg/kg pirfenidone in the bleomycin fibrosis model. It reduced lung weight at 5 mg/kg bid and showed clear evidence of protective effects in histological studies. In a kidney fibrosis model, dose-dependent reduction of fibrosis, but not collagen deposition, at 1 to 5 mg/kg qd was observed. Five analogs prepared were shown to have better potency and pharmacokinetic properties, although oral potency remained lower than potency after intraperitoneal administration  [&lt;ulink linkID="1715562" linkType="Reference"&gt;1715562&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1009875">Fidelta Ltd</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1009875">Fidelta Ltd</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2015-11-10T00:00:00.000Z</StatusDate><Source id="1715562" type="CONFERENCE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1715562" linkType="reference" linkID="1715562"&gt;1715562&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>